Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 6/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 6/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797350 | 0.89 | SSTR4 (0.42) | TACR2SSTR4MCHR1SSTR3SSTR5 | |
| SCHEMBL2797352 | 0.89 | SSTR4 (0.42) | TACR2SSTR4MCHR1SSTR3SSTR5 | |
| SCHEMBL25414267 | 0.81 | MCHR1 (0.39) | SSTR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL25412293 | 0.81 | SLC6A2 (0.43) | SSTR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL25412287 | 0.81 | SLC6A2 (0.43) | SSTR4MCHR1SSTR3SSTR5SSTR2 | |
| SCHEMBL2313867 | 0.80 | TLR4 (0.39) | MCHR1LGALS8TACR1 | |
| SCHEMBL28539502 | 0.80 | SSTR4 (0.42) | TACR2SSTR4MCHR1SSTR3SSTR5 | |
| SCHEMBL2314211 | 0.79 | TLR4 (0.44) | MCHR1PTPN1 | |
| SCHEMBL2796378 | 0.78 | NT5E (0.39) | TACR2PTPN1CDC25BNT5ELMNA | |
| SCHEMBL2796377 | 0.78 | NT5E (0.39) | TACR2PTPN1CDC25BNT5ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915383-B2 | Method of separating a peptidoglycan recognition protein from a hemolymph Tenebrio molitor larvae | YUHAN CORPORATION (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20080312408-A1 | Method of Separating a Peptidoglycan Recognition Protein From a Hemolymph Tenebrio Molitor Larvae | YUHAN CORPORATION (KR) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312408-A1 | Method of Separating a Peptidoglycan Recognition Protein From a Hemolymph Tenebrio Molitor Larvae | LRBA, CUTA, TLL1 | TACR2 2530/4885SSTR4 2284/4885MCHR1 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.